C57BL/6J mice bearing intracranial CT-2A high-grade gliomas were treated with anti-TIM3 or a control once per week or with anti–PD-1 three times per week for 3 weeks starting on day 7 after tumor implantation. This evidence concerns the gene HAVCR2 and glioma.